NPP
GILD icon

New Potomac Partners’s Gilead Sciences GILD Stock Holding History

New Potomac Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,275
Closed -$987K – 64
2021
Q1 		$987K Hold
15,275
– – 0.73% 47
2020
Q4 		$890K Sell
15,275
-10,674
-41% -$644K 0.64% 47
2020
Q3 		$1.64M Sell
25,949
-406
-2% -$28.2K 1.31% 33
2020
Q2 		$2.03M Sell
26,355
-1,090
-4% -$83.5K 1.81% 22
2020
Q1 		$2.05M Sell
27,445
-795
-3% -$54.9K 2.24% 14
2019
Q4 		$1.83M Buy
+28,240
New +$1.84M 1.71% 28

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

New Potomac Partners's GILD Position: Q2 2021 in Review

New Potomac Partners sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 15,275 shares — an estimated $987K sold.

New Potomac Partners first reported a position in GILD in Q4 2019 and held it in 6 quarters. The position peaked at $2.05M in Q1 2020. 1,546 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

  • New Potomac Partners reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
  • New Potomac Partners sold 15,275 Gilead Sciences shares in Q2 2021, an estimated $987K.
  • New Potomac Partners first reported a position in Gilead Sciences in Q4 2019 and held it in 6 quarters.
  • New Potomac Partners's Gilead Sciences position peaked at $2.05M in Q1 2020.
  • 1,546 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on New Potomac Partners's 13F filing for Q2 2021, filed 2 Aug 2021.